PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer
Shots:
- The company plans to initiate a P-III trial to evaluate PDS0101 + Keytruda vs Keytruda monotx. in patients with unresectable, recurrent/metastatic HPV 16+ HNSCC at ~90-100 sites globally. The trial is expected to be initiated in Q4’23
- In the previous studies, patients treated with the combination therapy achieved ORR (41%) and an overall survival rate of 87% @9mos. in 17 evaluable patients with HPV16 & PD-L1+ recurrent or metastatic HNSCC, was well tolerated with no treatment-related grade 3 or 4 AEs
- PDS0101 + Keytruda received FTD for HPV16+ HNSCC. The company has completed tech transfer, scale-up, and manufacturing activities required to initiate the trial & plans to submit an amended IND application to the US FDA in Q3’23
Ref: pds biotech| Image: pds biotech
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
